iRhythm Technologies
IRTC

$67.20

3.05%

Market Cap: $2.1B

About: iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

Employees: 2,000

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

63% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 64

3.01% more ownership

Funds ownership: 111.15% [Q1] → 114.16% (+3.01%) [Q2]

4% less capital invested

Capital invested by funds: $3.99B [Q1] → $3.82B (-$171M) [Q2]

10% less funds holding

Funds holding: 249 [Q1] → 225 (-24) [Q2]

46% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 52

48% less call options, than puts

Call options by funds: $17.2M | Put options by funds: $32.8M

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$100

49%

upside

Avg. target

$120

79%

upside

High target

$145

116%

upside

9 analyst ratings

9 positive

100%

0 neutral

0%

0 negative

0%

Citigroup Joanne Wuensch 66% 1-year accuracy 25 / 38 met price target	64%upside $110	Buy Maintained	22 Aug 2024
JP Morgan Allen Gong 56% 1-year accuracy 5 / 9 met price target	49%upside $100	Overweight Maintained	2 Aug 2024
Oppenheimer Suraj Kalia 53% 1-year accuracy 9 / 17 met price target	116%upside $145	Outperform Maintained	2 Aug 2024
Baird Mike Polark 57% 1-year accuracy 4 / 7 met price target	64%upside $110	Outperform Maintained	2 Aug 2024
Truist Securities Richard Newitter 67% 1-year accuracy 29 / 43 met price target	74%upside $117	Buy Reiterated	2 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about IRTC published over the past 30 days

iRhythm Technologies Announces Results of GUARD-AF Trial

GUARD-AF trial results presented at European Society of Cardiology (ESC) Congress 2024 Leveraging iRhythm's Zio ® patch-based long-term continuous monitoring (LTCM), GUARD-AF is the largest randomized trial in a primary care setting to evaluate the impact of screening for undiagnosed atrial fibrillation (AF) Screening with iRhythm's Zio ® XT 1 LTCM led to increase in new diagnosis of AF (5.0% vs 3.3%) over an average follow-up of 15 months. No difference in stroke hospitalization vs usual care in the context of reduced statistical power due to truncated enrollment and follow-up.

iRhythm Technologies Announces Results of GUARD-AF Trial

Zacks Investment Research

iRhythm Technologies Launches Zio Monitoring Across Europe

IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.

iRhythm Technologies Launches Zio Monitoring Across Europe

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio® monitor and Zio® long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union's CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union's CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union's CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union's CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

iRhythm Technologies to Participate in Upcoming Investor Conferences in September

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern Time Wells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern Time Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 2:00 pm Eastern time Those interested in listening to the presentations may do so by accessing the live and archived webcast of the events on the “Events & Presentations” section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease.

iRhythm Technologies to Participate in Upcoming Investor Conferences in September

Zacks Investment Research

All You Need to Know About iRhythm Technologies (IRTC) Rating Upgrade to Buy

iRhythm Technologies (IRTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About iRhythm Technologies (IRTC) Rating Upgrade to Buy

iRhythm Technologies, Inc. (IRTC) Q2 2024 Earnings Call Transcript

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q1 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - President and CEO Brice Bobzien - Chief Financial Officer Daniel Wilson - EVP of Corporate Development and Investor Relations Conference Call Participants Margaret Andrew - William Blair Allen Gong - JPMorgan Marie Thibault - BTIG LLC David Rescott - Baird Nathan Treybeck - Wells Fargo Joanne Wuensch - Citigroup Mike Polark - Wolfe Research Ravi Misra - Truist David Saxon - Needham & Company Suraj Kalia - Oppenheimer Operator Hello all, and welcome to iRhythm Technologies Second Quarter 2024 Earnings Conference Call. My name is Lydia and I'll be your operator today.

iRhythm Technologies, Inc. (IRTC) Q2 2024 Earnings Call Transcript

Zacks Investment Research

IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

IRhythm Technologies (IRTC) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.61 per share a year ago.

IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

See News Rankings